We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NASDAQ:NRIX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41 | -2.94% | 13.54 | 13.00 | 13.54 | 14.15 | 13.23 | 14.05 | 335,009 | 22:45:22 |
From Nov 2023 to May 2024
By Sabela Ojea
Nurix Therapeutics said the Food and Drug Administration has granted fast-track designation for NX-5948, its treatment for certain types of lymphocytic cancer.
NX-5948 is a degrader of Bruton's tyrosine kinase and is being studied to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The clinical-stage biopharmaceutical company on Tuesday said the designation follows encouraging safety and efficacy data from its ongoing Phase 1 clinical trial.
The FDA's fast-track designation is aimed at facilitating and expediting the development and review of drug candidates.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 16, 2024 16:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Nurix Therapeutics Chart |
1 Month Nurix Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
